Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial
Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, Victoria Gensch, Peter Thuss‐Patience, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Carsten Bokemeyer, Christian Müller, Peter Reichardt, Martin Sökler, Daniel Pink, Stefan Probst, Thorsten O Goetze, Salah E Al‐Batran, Sonja Loges, Melanie Janning · 2026
Read Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial by Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, Victoria Gensch, Peter Thuss‐Patience, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Carsten Bokemeyer, Christian Müller, Peter Reichardt, Martin Sökler, Daniel Pink, Stefan Probst, Thorsten O Goetze, Salah E Al‐Batran, Sonja Loges, Melanie Janning (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13432362.txt.
Description
Hille and colleagues searched for blood markers that predict who fares poorly on ramucirumab. Ramucirumab is a vessel-blocking antibody used as second-line therapy for advanced stomach and junction cancers. The search ran within the phase II RAMIRIS trial. Plasma from 99 patients was sampled at baseline and during treatment. The team measured placental growth factor, carbonic anhydrase IX, and tryptase levels.
Placental growth factor rose substantially during therapy. Carbonic anhydrase spiked briefly then eased, and tryptase stayed flat across the sampled timepoints. High growth factor levels at baseline carried a hazard ratio of 1.75 for death in unadjusted analysis. That signaled shorter survival for those patients. After adjustment, only the early on-treatment level kept statistical support. Its hazard ratio was 1.85 at the start of cycle two. Neither of the other two markers tracked survival consistently. The authors label all findings hypothesis-generating, pending validation.
Catalog record
| CREATOR | Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, Victoria Gensch, Peter Thuss‐Patience, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Carsten Bokemeyer, Christian Müller, Peter Reichardt, Martin Sökler, Daniel Pink, Stefan Probst, Thorsten O Goetze, Salah E Al‐Batran, Sonja Loges, Melanie Janning |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |